Literature DB >> 10074910

Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors.

S Kyo1, T Kanaya, M Takakura, M Tanaka, A Yamashita, H Inoue, M Inoue.   

Abstract

Telomerase activity is involved in the maintenance of telomere length and is thought to be required for cellular immortality and oncogenesis. Three major subunits composing telomerase, human telomerase RNA (hTR), telomerase-associated protein (TPI) and human telomerase catalytic subunit (hTERT), have been identified. However, their functions and the regulatory mechanisms by which telomerase is activated have not been fully determined. In the present study, a total of 35 epithelial ovarian cancers, 5 ovarian low potential malignancies (LPM), 11 ovarian benign cysts and 12 normal ovaries, as well as various cell lines derived from ovarian cancers, were examined for the expression of hTR, TPI mRNA and hTERT mRNA. Correlations of expression with telomerase activity were evaluated. Reverse transcription-polymerase chain reaction (RT-PCR) analysis revealed that hTR and TPI mRNA were expressed in more than 80% of ovarian cancers, LPM, ovarian cysts and even in normal ovaries. However, hTERT mRNA was observed only in ovarian cancers, most of which exhibited telomerase activity. Normal ovarian tissues, ovarian cysts and LPM, most of which had no telomerase activity, did not express hTERT. Five telomerase-positive ovarian cancer cell lines expressed each of the telomerase subunits, whereas 2 telomerase-negative normal primary fibroblast cell lines expressed TPI mRNA and hTR, but not hTERT mRNA. There was a significant correlation of telomerase activity with hTERT mRNA expression but not with TPI or hTR expression. Expression of hTERT is thus specific to cancer lesions and appears to be a rate-limiting determinant of the enzymatic activity of human telomerase. Up-regulation of hTERT may play a critically important role in the development of ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074910     DOI: 10.1002/(sici)1097-0215(19990315)80:6<804::aid-ijc2>3.0.co;2-b

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).

Authors:  S Kyo; M Takakura; T Taira; T Kanaya; H Itoh; M Yutsudo; H Ariga; M Inoue
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.

Authors:  M J Choi; K H Cho; S Lee; Y J Bae; K J Jeong; S Y Rha; E J Choi; J H Park; J M Kim; J-S Lee; G B Mills; H Y Lee
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

3.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 4.  Telomeres and immunological diseases of aging.

Authors:  Nicolas P Andrews; Hiroshi Fujii; Jörg J Goronzy; Cornelia M Weyand
Journal:  Gerontology       Date:  2009-12-17       Impact factor: 5.140

5.  Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT.

Authors:  K Fujimoto; S Kyo; M Takakura; T Kanaya; Y Kitagawa; H Itoh; M Takahashi; M Inoue
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

6.  The hTERT-VNTR2-2nd alleles are involved in genomic stability in gastrointestinal cancer.

Authors:  Jeong-Ah Kwon; Mi-So Jeong; Se-Lyun Yoon; Jeong-Yeon Mun; Min-Hye Kim; Gi-Eun Yang; Seong-Hwan Park; Jin-Woong Chung; Yung Hyun Choi; Hee-Jae Cha; Sun-Hee Leem
Journal:  Genes Genomics       Date:  2019-11-05       Impact factor: 1.839

Review 7.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

8.  Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.

Authors:  Satoru Kyo; Kenkichi Masutomi; Yoshiko Maida; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Masaaki Tanaka; Mitsuko Takarada; Isamu Sugawara; Seishi Murakami; Takahiro Taira; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

Authors:  M Takakura; M Nakamura; S Kyo; M Hashimoto; N Mori; T Ikoma; Y Mizumoto; T Fujiwara; Y Urata; M Inoue
Journal:  Cancer Gene Ther       Date:  2010-01       Impact factor: 5.987

10.  Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma.

Authors:  Jia-Hua Zhou; Hong-Mei Zhang; Quan Chen; Dong-Dong Han; Fei Pei; Li-Shan Zhang; De-Tong Yang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.